Acasti Pharma Files 8-K: Director Changes & Shareholder Votes
Ticker: GRCE · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Acasti Pharma INC. (GRCE) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, filing, corporate-actions
TL;DR
Acasti Pharma's 8-K details director changes and upcoming votes. Governance shifts incoming.
AI Summary
Acasti Pharma Inc. filed an 8-K on September 30, 2024, reporting on the departure of directors, election of new directors, and compensatory arrangements. The filing also covers matters submitted to a vote of security holders and includes financial statements and exhibits. The company's principal executive offices are located at 103 Carnegie Center, Suite 300, Princeton, NJ 08540.
Why It Matters
This filing provides crucial updates on the company's governance and operational decisions, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Changes in directorship and compensatory arrangements can signal shifts in company strategy or internal dynamics, requiring investor attention.
Key Players & Entities
- Acasti Pharma Inc. (company) — Registrant
- September 30, 2024 (date) — Date of Report
- 103 Carnegie Center Suite 300 Princeton , New Jersey 08540 (location) — Principal Executive Offices
FAQ
What specific items were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific proposals are not detailed in the provided text.
Who are the new directors elected to Acasti Pharma's board?
The filing mentions the election of directors, but the names of the newly elected directors are not specified in the provided text.
Are there any details on the compensatory arrangements for Acasti Pharma's officers?
The filing notes that compensatory arrangements of certain officers are covered, but the specifics of these arrangements are not included in the excerpt.
What is the SIC code for Acasti Pharma Inc.?
The Standard Industrial Classification (SIC) code for Acasti Pharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When is Acasti Pharma's fiscal year end?
Acasti Pharma's fiscal year ends on March 31st (0331).
Filing Stats: 1,062 words · 4 min read · ~4 pages · Grade level 13.7 · Accepted 2024-09-30 16:31:03
Filing Documents
- ef20036442_8k.htm (8-K) — 59KB
- ef20036442_ex10-1.htm (EX-10.1) — 166KB
- 0001140361-24-042352.txt ( ) — 401KB
- acst-20240930.xsd (EX-101.SCH) — 4KB
- acst-20240930_lab.xml (EX-101.LAB) — 21KB
- acst-20240930_pre.xml (EX-101.PRE) — 16KB
- ef20036442_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As described in Item 5.07 below, Acasti Pharma Inc. (the "Company") held its Annual and Special Meeting of Shareholders on September 30, 2024 (the "Meeting"). At the Meeting, the Company's shareholders approved the Acasti Pharma Inc. 2024 Equity Incentive Plan (the "2024 Plan"). A detailed description of the 2024 Plan was included in the Company's Proxy Statement/Prospectus filed with the U.S. Securities and Exchange Commission on August 7, 2024 (the "Proxy Statement"). Such description of the 2024 Plan does not purport to be complete and is qualified in its entirety by reference to the 2024 Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 30, 2024, the Company held the Meeting. Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Company's board of director's solicitation. Holders of a total of 7,149,326 of the Company's common shares were present or represented by proxy at the Meeting, representing 70.50% of the Company's 10,139,861 common shares that were outstanding and entitled to vote at the Meeting as of the record date of August 6, 2024. Set forth below are the matters acted upon by the Company's shareholders at the Meeting and the final voting results on each matter. Each of the proposals is described in further detail in the Proxy Statement. Proposal No. 1 – Election of Directors The following nominees were elected as directors by the votes indicated to serve until the close of the Company's next annual meeting of shareholders or until his successor is elected or appointed: Nominee Votes For Withheld Broker Non-Votes Vimal Kavuru 5,883,771 71,334 1,194,221 A. Brian Davis 5,902,562 52,543 1,194,221 S. George Kottayil 5,902,813 52,292 1,194,221 Prashant Kohli 5,902,397 52,708 1,194,221 Edward Neugeboren 5,902,677 52,428 1,194,221 Proposal No. 2 – Appointment of Independent Registered Public Accounting Firm The proposal to appoint KPMG as the Company's independent registered public accounting firm until the close of the Company's next annual meeting of shareholders and to authorize the Company's board of directors to fix its remuneration was approved by the shareholders by the following vote: For Against Abstain Broker Non-Votes 7,055,362 65,827 28,137 0 Proposal No. 3 – Advisory Vote to Approve Named Executive Officer Compensation The proposal to approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers as described in
01
Item 9.01 Exhibits. (d) Exhibits Exhibit Description 10.1 Acasti Pharma Inc. 2024 Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 30, 2024 ACASTI PHARMA INC. By: /s/ Prashant Kohli Name: Prashant Kohli Title: Chief Executive Officer